Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.

This study has been completed.
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
Laval University Identifier:
First received: July 14, 2006
Last updated: NA
Last verified: November 2002
History: No changes posted

July 14, 2006
July 14, 2006
January 2003
Not Provided
Body weight and fat mass loss at the end of the 15-week weight loss supplemented intervention.
Same as current
No Changes Posted
  • Change in metabolic variables at the end of the 15-week calcium/vitamin D supplemented weight loss intervention
  • Change in energy/macronutrient intake at the end of the 15-week calcium/vitamin D supplemented weight loss intervention
Same as current
Not Provided
Not Provided
Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Calcium/Vitamin D Supplementation (Caltrate 600+ D) on Body Weight and Fat Loss in Overweight and Obese Individuals on a Weight-Reducing Program.
The aim of this study was to assess the effect of calcium/vitamin D supplementation (Caltrate 600 +D®) on body weight loss during a weight-reducing program

The effect of a calcium supplementation on body weight loss is inconclusive and some studies have suggested that adequate calcium intake can have a favourable effect on some metabolic variables. The objectives of this study were to evaluate the impact of (Caltrate 600 + D ®) on body composition and various indicators of metabolic health in overweight and obese females characterised by a usual low daily calcium intake, on a weight-reducing program.

The main hypotheses of this study were:

  • Caltrate 600 +D® increases body weight and fat mass losses of individuals on a weight-reducing program.
  • Caltrate 600 +D® improves the metabolic profile of these subjects, independently of variations promoted by body fat loss.
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Obesity
  • Overweight
  • Drug: Caltrate® 600 + D
  • Behavioral: Weight loss intervention
Not Provided
Major GC, Alarie FP, Doré J, Tremblay A. Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: potential link with a calcium-specific appetite control. Br J Nutr. 2009 Mar;101(5):659-63.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2005
Not Provided

Inclusion Criteria:

  • Daily calcium intake below 800mg/day
  • Stable body weight
  • Body mass index (BMI) between 27-40kg/m2
  • Less than 3 periods of 20 minutes of physical exercise/week
  • General good health
  • Normal blood pressure values
  • Normal cholesterol levels
  • Normal thyroid hormone levels
  • No participation in another clinical trial within 6 months of screening
  • Coffee consumption ≤ 5 cups/day.

Exclusion Criteria:

  • Breast feeding, pregnant or menopaused women
  • Use of calcium supplements within 30 days of screening
  • Cholesterol levels requiring pharmaceutical treatment
  • Smoking
  • Use of medication that could affect body weight
30 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Laval University
Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Angelo Tremblay, PhD Laval University
Laval University
November 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP